The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Blood

• Publication date

  2003-11-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2003-02-0515PMID 12881320
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence for the detection of the normal counterpart of hodgkin and sternberg‐reed cells

  2007cited by this paper
• Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates

  2004cited by this paper
• The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

  2002cited by this paper
• Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells.

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• CD30 and CD117 (c-kit) Used in Combination Are Useful for Distinguishing Embryonal Carcinoma from Seminoma

  2002cited by this paper
• CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540.

  2002cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin–Reed-Sternberg cells

  2002cited by this paper
• Rituximab: mechanisms and applications

  2001cited by this paper
• Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies

  2000cited by this paper
• CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

  2000cited by this paper
• Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.

  2000cited by this paper
• Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?

  2000cited by this paper
• Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells

  1999cited by this paper
• High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.

  1999cited by this paper
• CD30 in normal and neoplastic cells.

  1999cited by this paper
• CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway.

  1999cited by this paper
• CD30 expression is common in mediastinal large B-cell lymphoma.

  1999cited by this paper
• CD30: expression and function in health and disease.

  1998cited by this paper
• Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells

  1998cited by this paper
• BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

  1998cited by this paper
• Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.

  1996cited by this paper
• Reverse signaling via CD30 ligand.

  1996cited by this paper
• Development of new ricin A‐chain immunotoxins with potent anti‐tumor effects against human hodgkin cells in vitro and disseminated Hodgkin tumors in scid mice using high‐affinity monoclonal antibodies directed against the CD30 antigen

  1995cited by this paper
• Shedding of the soluble form of CD30 from the Hodgkin‐analogous cell line L540 is strongly inhibited by a new CD30‐specific antibody (Ki‐4)

  1995cited by this paper
• Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.

  1994cited by this paper
• Indications for autologous bone marrow transplantation in Hodgkin's disease.

  1992cited by this paper
• In vivo targeting of Hodgkin and Reed‐Sternberg cells of Hodgkin's disease with monoclonal antibody Ber‐H2 (CD30): immimohistological evidence

  1992cited by this paper
• Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.

  1991cited by this paper
• Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.

  1990cited by this paper
• Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells.

  1987cited by this paper
• Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells

  1982cited by this paper
• Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.

  1982cited by this paper
• Hodgkin's disease: Unfolding concepts concerning its nature, management and prognosis

  1980cited by this paper
• Combination chemotherapy in the treatment of advanced Hodgkin's disease.

  1975cited by this paper
• Combination chemotherapy in the treatment of advanced Hodgkin's disease.

  1970cited by this paper

• Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.

  2026cites this paper
• Next-generation all-in-one CRISPR/Cas9 multiply-edited CD30CAR-T cells: Potency despite risk of translocations

  2026cites this paper
• CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

  2025cites this paper
• CAR-T Cell Therapy for Classical Hodgkin Lymphoma

  2023influential citation
• CD30 as a therapeutic target in adult haematological malignancies: Where are we now?

  2023cites this paper
• Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved ADCs—A Necessity for Future ADC Research and Development

  2021cites this paper
• Xenograft models for pediatric cancer therapies

  2021cites this paper
• Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development

  2021cites this paper
• Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma

  2020cites this paper
• Immunopathology and Immunotherapy of Hodgkin Lymphoma

  2020cites this paper
• Antibody–Drug Conjugates: Empowering Antibodies for the Fight Against Cancer

  2019cites this paper
• Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.

  2018cites this paper
• Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies

  2018cites this paper
• The translational science of hodgkin lymphoma

  2018cites this paper
• Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells

  2017cites this paper
• Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions

  2017cites this paper
• Releasing the Brakes in Cancer

  2016cites this paper
• CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

  2016cites this paper
• ADCs Approved for Use: Brentuximab Vedotin

  2016cites this paper
• Brentuximab vedotin for treating Hodgkin’s lymphoma: an analysis of pharmacology and clinical efficacy

  2015cites this paper
• Brentuximab: a major advance in treatment of CD30-positive malignancies

  2015cites this paper
• CD30 as a Therapeutic Target for Lymphoma

  2014cites this paper
• Antibodies and antibody‐drug conjugates in the treatment of Hodgkin lymphoma

  2014cites this paper
• An update on emerging drugs for Hodgkin lymphoma

  2014cites this paper
• Brentuximab vedotin in CD30-expressing cutaneous T-cell lymphoma

  2014cites this paper
• Current Therapies for T-cell Lymphomas

  2013cites this paper
• Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

  2013cites this paper
• Novel targeted therapies in peripheral T cell lymphoma.

  2013cites this paper
• Monoclonal Antibodies (mAb) in the Therapy of T-Cell Lymphomas

  2013cites this paper
• therapeutic potential From Hodgkin's disease to Hodgkin lymphoma: biological insights and

  2013cites this paper
• Primary Cutaneous and Systemic CD30+ T-cell Lymphoproliferative Disorders

  2013cites this paper
• Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma

  2013cites this paper
• Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies

  2013cites this paper
• Treatment strategies for peripheral T-cell lymphomas.

  2013cites this paper
• Best Practice & Research Clinical Haematology

  2013cites this paper
• Anaplastic large cell lymphoma, ALK-negative.

  2013cites this paper
• Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma

  2012cites this paper
• Anaplastic large cell lymphoma, ALK-positive.

  2012cites this paper
• Antibody‐Mediated Drug Delivery System for Lymphatic Targeting Treatment

  2012cites this paper
• Brentuximab Vedotin

  2012cites this paper
• Hodgkin lymphoma.

  2012cites this paper
• CD30: an important new target in hematologic malignancies

  2011influential citation
• Lymphome de Hodgkin de l’adulte

  2011cites this paper
• The Use of Mouse Models to Study Leukemia/Lymphoma and Assess Therapeutic Approaches

  2011cites this paper
• Peripheral T-cell lymphoma.

  2011cites this paper
• Relapsed and Refractory Hodgkin Lymphoma

  2011cites this paper
• Novel antibodies against follicular non-Hodgkin's lymphoma.

  2011cites this paper
• Best Practice & Research Clinical Haematology

  2011cites this paper
• Targetable molecular pathways in classical Hodgkin's lymphoma

  2011cites this paper
• Anti-CD30 Antibodies for Hodgkin Lymphoma

  2010cites this paper
• TNF-α-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species

  2010cites this paper
• 2 Murine L 1210 and P 388 Leukemias

  2010cites this paper
• New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies

  2010influential citation
• Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

  2010cites this paper
• Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.

  2010cites this paper
• Emerging drugs for Hodgkin's lymphoma

  2010cites this paper
• New Therapeutic Frontiers for Childhood Non-Hodgkin Lymphoma

  2010cites this paper
• Susceptibility of human T‐cell leukemia virus type I‐infected cells to humanized anti‐CD30 monoclonal antibodies in vitro and in vivo

  2010cites this paper
• Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.

  2010cites this paper
• CD30: a suitable target for immunotherapy?

  2009cites this paper
• Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma

  2009cites this paper
• A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

  2009cites this paper
• Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.

  2009cites this paper
• In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma

  2009cites this paper
• The Role of Tumor Necrosis Factor Receptor Super-Family Member CD30 and its Cognate Ligand CD30L for the Interplay of Immune Effector Cells

  2009cites this paper
• Drug development for recurrent and refractory classical Hodgkin lymphoma

  2009influential citation
• Is there a role for immunotherapy in Hodgkin’s disease?

  2009cites this paper
• Human antibody RNase fusion protein targeting CD30+ lymphomas.

  2008cites this paper
• Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas

  2008cites this paper
• Human Monoclonal Antibodies from Transgenic Mice

  2008cites this paper
• Immunotherapies for Hodgkin's lymphoma.

  2008cites this paper
• Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas

  2008cites this paper
• Newer monoclonal antibodies for hematological malignancies.

  2008cites this paper
• Treatment of CD30-positive diseases, such as Hodgkin's lymphoma, by administration of a combination of sheddase inhibitor and anti-CD30 immunotherapeutic agents

  2008cites this paper
• Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1

  2007cites this paper
• Relapsed and Refractory Hodgkin Lymphoma: Transplantation Strategies and Novel Therapeutic Options

  2007cites this paper
• Report on the 1st International Workshop of the German Competence Network Malignant Lymphomas

  2007cites this paper
• Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas

  2007cites this paper
• Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells

  2007cites this paper
• Individualized target therapy of malignant lymphomas: an outlook.

  2007cites this paper
• Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.

  2007cites this paper
• Treatment of Relapsed/Refractory Hodgkin Lymphoma

  2007cites this paper
• Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

  2007cites this paper
• Novel small molecules in the treatment of lymphomas.

  2006cites this paper
• Management of early stage Hodgkin's lymphoma.

  2006cites this paper
• CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.

  2006cites this paper
• Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

  2006cites this paper
• Isolated anti-cd30 antibody (versions); host cell, method of obtaining chimeric or humanised version of anti-cd30 antibodies (versions), method of inhibiting growth of cells cd30+ and method of inhibiting growth of tumour cells expressing cd30

  2006cites this paper
• Current Strategies and New Approaches in the Treatment of Hodgkin’s Lymphoma

  2006cites this paper
• CD 32 B , the human inhibitory Fc-receptor IIB , as a target for monoclonal antibody therapy of B-cell lymphoma

  2006cites this paper
• SGN-30 (Seattle genetics).

  2006cites this paper
• Anaplastic large-cell lymphoma, T-/null-cell type.

  2006cites this paper
• 3 Re-induction Therapy with Ifosfamide / Vinorelbine ( IV )

  2006cites this paper
• Childhood and adolescent non‐Hodgkin lymphoma: New insights in biology and critical challenges for the future

  2005cites this paper
• Molecular mechanisms of T cell homing in Hodgkin's lymphoma : implications for T-cell-based therapies.

  2005cites this paper
• From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential.

  2005cites this paper
• Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.

  2005cites this paper
• CD30: a suitable target for immunotherapy? The CD30

  2005cites this paper
• Monoclonal antibody therapy of leukaemias and lymphomas

  2005cites this paper
• Current treatment strategies of the German Hodgkin Study Group (GHSG)

  2005cites this paper